1. Ruzurgi is a rare disease drug for Lambert-Eaton myasthenic syndrome for children ages 6 to 17. The disorder affects the connection between nerves and muscles, causing weakness in affected patients.
2. Vyndaqel is approved to treat heart disease caused by transthyretin mediated amyloidosis, which is rare and often fatal.
3. Vyndamax, a capsule manufactured by a subsidiary of Pfizer, also was approved to treat heart disease caused by transthyretin mediated amyloidosis.
4. The eMurmur ID program is a cloud-connected mobile system using advanced machine learning to identify heart murmurs.
More articles about supply chain:
Philadelphia hospital investigating theft of $25K in endoscopes
The 1st pediatric dengue vaccine, a wearable arrhythmia monitor & more: 5 recent FDA approvals
FDA won’t ban breast implants linked to cancer for now
